Aceso Life Science Group Limited (HKG:0474)

Aceso Life Science Group Cash Flow Statement

Financials in millions HKD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	-895	-462	-264	-370	-376
Depreciation & Amortization	43	50	52	68	63
Loss (Gain) From Sale of Investments	171	316	46	501	441
Asset Writedown & Restructuring Costs	612	89	6	-89	88
Loss (Gain) on Equity Investments	94	325	209	74	-288
Stock-Based Compensation	-	-	3	7	49
Change in Accounts Payable	-2	-7	7	2	-14
Change in Trading Asset Securities	10	29	24	-52	-48
Change in Other Net Operating Assets	-19	-102	74	255	109
Other Operating Activities	-10	-277	45	-88	152
Operating Cash Flow	17	-37	214	316	179
Operating Cash Flow Growth	-	-	-32.28%	76.54%	-
Capital Expenditures	-2	-11	-24	-57	-15
Sale of Property, Plant & Equipment	17	-	8	14	4
Divestitures	-	-	1	-	-
Investment in Securities	-60	30	-86	4	-
Other Investing Activities	382	56	-11	-402	11
Investing Cash Flow	337	75	-112	-441	-
Short-Term Debt Issued	-	1	-	24	-
Long-Term Debt Issued	-	693	481	882	214
Total Debt Issued	-	694	481	906	214
Short-Term Debt Repaid	-	-	-20	-12	-
Long-Term Debt Repaid	-486	-855	-593	-588	-693
Total Debt Repaid	-486	-855	-613	-600	-693
Net Debt Issued (Repaid)	-486	-161	-132	306	-479
Issuance of Common Stock	-	-	-	-	150
Repurchase of Common Stock	-13	-	-9	-5	-
Other Financing Activities	-88	278	43	-175	-46
Financing Cash Flow	-587	117	-98	126	-375
Foreign Exchange Rate Adjustments	15	8	-12	-4	12
Net Cash Flow	-218	163	-8	-3	-184
Free Cash Flow	15	-48	190	259	164
Free Cash Flow Growth	-	-	-26.64%	57.93%	-
Free Cash Flow Margin	-	-436.36%	91.79%	152.35%	-
Free Cash Flow Per Share	0.00	-0.01	0.03	0.04	0.02
Cash Interest Paid	93	142	113	152	114
Cash Income Tax Paid	5	10	-	3	11

Updated Dec 20, 2024. Source: S&P Global Market Intelligence. Financial Services template. Financial Sources.